EVALUATION OF SAFETY OF DRUG THERAPY IN CLINICAL PRACTICE
the present review is devoted to an actual problem of safety of pharmacotherapy in clinical practice; the particular attention is paid to the state of this problem in pediatrics. Information about pharmacovigilance is proposed; criteria of definition, methods of collecting (their advantages and limi...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Book |
| Published: |
IRBIS LLC,
2015-03-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_b0c531df7da94e828481275ea64889f3 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a M. N. Kostyleva |e author |
| 700 | 1 | 0 | |a Yu. B. Belousov |e author |
| 700 | 1 | 0 | |a A. N. Gratsianskaya |e author |
| 700 | 1 | 0 | |a S. S. Postnikov |e author |
| 245 | 0 | 0 | |a EVALUATION OF SAFETY OF DRUG THERAPY IN CLINICAL PRACTICE |
| 260 | |b IRBIS LLC, |c 2015-03-01T00:00:00Z. | ||
| 500 | |a 2070-4909 | ||
| 500 | |a 2070-4933 | ||
| 520 | |a the present review is devoted to an actual problem of safety of pharmacotherapy in clinical practice; the particular attention is paid to the state of this problem in pediatrics. Information about pharmacovigilance is proposed; criteria of definition, methods of collecting (their advantages and limitations), account and analysis of the adverse reactions of drugs in post-marketing period are described. The off label use of drugs in children and a role of clinical pharmacologist in the adverse reactions of drugs monitoring in a hospital is discussed. | ||
| 546 | |a RU | ||
| 690 | |a safety of pharmacotherapy | ||
| 690 | |a adverse drug reactions | ||
| 690 | |a monitoring of drug safety | ||
| 690 | |a pediatrics | ||
| 690 | |a pharmacovigilance | ||
| 690 | |a methods of pharmacovigilance | ||
| 690 | |a clinical pharmacologist | ||
| 690 | |a off label use of drugs | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 690 | |a Economics as a science | ||
| 690 | |a HB71-74 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Фармакоэкономика, Vol 7, Iss 1, Pp 27-32 (2015) | |
| 787 | 0 | |n https://www.pharmacoeconomics.ru/jour/article/view/57 | |
| 787 | 0 | |n https://doaj.org/toc/2070-4909 | |
| 787 | 0 | |n https://doaj.org/toc/2070-4933 | |
| 856 | 4 | 1 | |u https://doaj.org/article/b0c531df7da94e828481275ea64889f3 |z Connect to this object online. |